The fat side of prostate cancer

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1831, Issue 10, 2013, Pages 1518-1532

  Zadra, Giorgia ^a   Photopoulos, Cornelia ^a   Loda, Massimo ^a,b,c,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Fatty acids; Imaging; Lipid metabolism; Metabolic diseases; Prostate cancer

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ABIRATERONE ACETATE; CERULENIN; DOCETAXEL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; METFORMIN; PREDNISONE; TETRAHYDROLIPSTATIN;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CASTRATION RESISTANT PROSTATE CANCER; CELL METABOLISM; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DRUG MECHANISM; DRUG POTENCY; FAT INTAKE; FATTY ACID SYNTHESIS; GLYCOLYSIS; HUMAN; LIPID METABOLISM; LIPOGENESIS; LIPOLYSIS; METABOLIC SYNDROME X; MOLECULAR IMAGING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STEROIDOGENESIS;

EID: 84885180245     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2013.03.010     Document Type: Review

References (211)

1. R. Siegel, E. Ward, O. Brawley, A. Jemal, Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths, CA Cancer J. Clin. 61 (2011) 212-236.
2. M. Djulbegovic, M.M. Neuberger, P. Dahm, Prostate-cancer mortality after PSA screening, N. Engl. J. Med. 366 (2012) 2228-2229, (author reply 2230-2221).
3. Y. Chen, N.J. Clegg, H.I. Scher, Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target, Lancet Oncol. 10 (2009) 981-991.
4. S. Bracarda, C. Logothetis, C.N. Sternberg, S. Oudard, Current and emerging treatment modalities for metastatic castration-resistant prostate cancer, BJU Int 107 (Suppl. 2) (2011) 13-20.
5. D.P. Petrylak, CM. Tangen, MH. Hussain, P.N. Lara Jr., JA Jones, ME. Taplin, PA Burch, D. Berry, C. Moinpour, M. Kohli, M.C. Benson, E.J. Small, D. Raghavan, E.D. Crawford, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N. Engl. J. Med. 351 (2004) 1513-1520. (Pubitemid 39315318)
6. AO. Sartor, Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space, J. Hematol. Oncol. 4 (2011) 18.
7. O. Warburg, On the origin of cancer cells, Science 123 (1956) 309-314.
8. M.G. Vander Heiden, Targeting cancer metabolism: a therapeutic window opens, Nat Rev. Drug Discov. 10 (2011) 671-684.
9. F.P. Kuhajda, K. Jenner, F.D. Wood, RA Hennigar, L.B. Jacobs, J.D. Dick, G.R Pasternack, Fatty acid synthesis: a potential selective target for antineoplastic therapy, Proc. Natl. Acad. Sci. U. S. A 91 (1994) 6379-6383. (Pubitemid 24200664)
10. J.V. Swinnen, T. Roskams, S. Joniau, H. Van Poppel, R. Oyen, L. Baert, W. Heyns, G. Verhoeven, Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer, Int J. Cancer 98 (2002) 19-22. (Pubitemid 34113412)
11. S. Rossi, E. Graner, P. Febbo, L. Weinstein, N. Bhattacharya, T. Onody, G. Bubley, S. Balk, M. Loda, Fatty acid synthase expression defines distinct molecular signatures in prostate cancer, Mol. Cancer Res. 1 (2003) 707-715. (Pubitemid 37025589)
12. JA Menendez, R. Lupu, Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis, Nat Rev. Cancer 7 (2007) 763-777. (Pubitemid 47469806)
13. J. Suburu, Y.Q. Chen, Lipids and prostate cancer, Prostaglandins Other Lipid Mediat 98 (2012) 1-10.
14. J.V. Swinnen, K. Brusselmans, G. Verhoeven, Increased lipogenesis in cancer cells: new players, novel targets, Curr. Opin. Clin. Nutr. Metab. Care 9 (2006) 358-365. (Pubitemid 44101970)
15. A. Ramirez de Molina, R. Gutierrez, MA Ramos, J.M. Silva, J. Silva, F. Bonilla, J.J. Sanchez, J.C. Lacal, Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy, Oncogene 21 (2002) 4317-4322. (Pubitemid 34753838)
16. A. Ramirez de Molina, A. Rodriguez-Gonzalez, R. Gutierrez, L. Martinez-Pineiro, J. Sanchez, F. Bonilla, R. Rosell, J. Lacal, Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers, Biochem. Biophys. Res. Commun. 296 (2002) 580-583.
17. A. Ramirez de Molina, D. Gallego-Ortega, J. Sarmentero, M. Banez-Coronel, Y. Martin-Cantalejo, J.C. Lacal, Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis, Cancer Res. 65 (2005) 5647-5653. (Pubitemid 40911165)
18. D. Gallego-Ortega, A. Ramirez de Molina, M.A. Ramos, F. Valdes-Mora, M.G. Barderas, J. Sarmentero-Estrada, J.C. Lacal, Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment, PLoS One 4 (2009) e7819.
19. R.T. Dorsam, J.S. Gutkind, G-protein-coupled receptors and cancer, Nat. Rev. Cancer 7 (2007) 79-94. (Pubitemid 46164746)
20. M.D. Resh, Palmitoylation of ligands, receptors, and intracellular signaling molecules, Sci. STKE 2006 (2006) re14.
21. M.E. Linder, R.J. Deschenes, Palmitoylation: policing protein stability and traffic, Nat. Rev. Mol. Cell Biol. 8 (2007) 74-84. (Pubitemid 46012016)
22. M.J. Nadolski, M.E. Linder, Protein lipidation, FEBS J. 274 (2007) 5202-5210. (Pubitemid 47512367)
23. F. Blasi, N. Sidenius, The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling, FEBS Lett. 584 (2010) 1923-1930.
24. C. Bergum, G. Zoratti, J. Boerner, K. List, Strong expression association between matriptase and its substrate prostasin in breast cancer, J. Cell. Physiol. 227 (2012) 1604-1609.
25. K. Willert, J.D. Brown, E. Danenberg, A.W. Duncan, I.L. Weissman, T. Reya, J.R. Yates III, R. Nusse, Wnt proteins are lipid-modified and can act as stem cell growth factors, Nature 423 (2003) 448-452. (Pubitemid 36626997)
26. R. Takada, Y. Satomi, T. Kurata, N. Ueno, S. Norioka, H. Kondoh, T. Takao, S. Takada, Monounsaturated fatty acid modification of Wnt protein: its role in Wnt secretion, Dev. Cell 11 (2006) 791-801. (Pubitemid 44804277)
27. M. Fiorentino, G. Zadra, E. Palescandolo, G. Fedele, D. Bailey, C. Fiore, P.L. Nguyen, T. Migita, R. Zamponi, D. Di Vizio, C. Priolo, C. Sharma, W. Xie, M.E. Hemler, L. Mucci, E. Giovannucci, S. Finn, M. Loda, Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer, Lab. Invest. 88 (2008) 1340-1348.
28. S.P. Staal, Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma, Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 5034-5037. (Pubitemid 17095859)
29. A. Bellacosa, J.R. Testa, S.P. Staal, P.N. Tsichlis, A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region, Science 254 (1991) 274-277. (Pubitemid 21917339)
30. A. Mor, M.R. Philips, Compartmentalized Ras/MAPK signaling, Annu. Rev. Immunol. 24 (2006) 771-800.
31. M. Buzzai, D.E. Bauer, R.G. Jones, R.J. Deberardinis, G. Hatzivassiliou, R.L. Elstrom, C.B. Thompson, The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation, Oncogene 24 (2005) 4165-4173. (Pubitemid 40961771)
32. Y. Liu, Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer, Prostate Cancer Prostatic Dis. 9 (2006) 230-234. (Pubitemid 44317255)
33. J.V. Swinnen, F. Vanderhoydonc, A.A. Elgamal, M. Eelen, I. Vercaeren, S. Joniau, H. Van Poppel, L. Baert, K. Goossens, W. Heyns, G. Verhoeven, Selective activation of the fatty acid synthesis pathway in human prostate cancer, Int. J. Cancer 88 (2000) 176-179.
34. T. Migita, S. Ruiz, A. Fornari, M. Fiorentino, C. Priolo, G. Zadra, F. Inazuka, C. Grisanzio, E. Palescandolo, E. Shin, C. Fiore, W. Xie, A.L. Kung, P.G. Febbo, A. Subramanian, L. Mucci, J. Ma, S. Signoretti, M. Stampfer, W.C. Hahn, S. Finn, M. Loda, Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer, J. Natl. Cancer Inst. 101 (2009) 519-532.
35. D.E. Vance, J.E. Vance, Biochemistry of Lipids, Lipoproteins and Membranes, Fourth ed. Elsevier Science, 2002.
36. H.G. Enoch, A. Catala, P. Strittmatter, Mechanism of rat liver microsomal stearyl-CoA desaturase. Studies of the substrate specificity, enzyme-substrate interactions, and the function of lipid, J. Biol. Chem. 251 (1976) 5095-5103.
37. J. Li, S.F. Ding, N.A. Habib, B.F. Fermor, C.B. Wood, R.S. Gilmour, Partial characterization of a cDNA for human stearoyl-CoA desaturase and changes in its mRNA expression in some normal and malignant tissues, Int. J. Cancer 57 (1994) 348-352. (Pubitemid 24168608)
38. J. Lu, H. Pei, M. Kaeck, H.J. Thompson, Gene expression changes associated with chemically induced rat mammary carcinogenesis, Mol. Carcinog. 20 (1997) 204-215. (Pubitemid 27508884)
39. S.F. Thai, J.W. Allen, A.B. DeAngelo, M.H. George, J.C. Fuscoe, Detection of early gene expression changes by differential display in the livers of mice exposed to dichloroacetic acid, Carcinogenesis 22 (2001) 1317-1322. (Pubitemid 32737350)
40. N. Yahagi, H. Shimano, K. Hasegawa, K. Ohashi, T. Matsuzaka, Y. Najima, M. Sekiya, S. Tomita, H. Okazaki, Y. Tamura, Y. Iizuka, K. Ohashi, R. Nagai, S. Ishibashi, T. Kadowaki, M. Makuuchi, S. Ohnishi, J. Osuga, N. Yamada, Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma, Eur. J. Cancer 41 (2005) 1316-1322. (Pubitemid 40813009)
41. V. Fritz, Z. Benfodda, G. Rodier, C. Henriquet, F. Iborra, C. Avances, Y. Allory, A. de la Taille, S. Culine, H. Blancou, J.P. Cristol, F. Michel, C. Sardet, L. Fajas, Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice, Mol. Cancer Ther. 9 (2010) 1740-1754.
42. K. Tamura, A. Makino, F. Hullin-Matsuda, T. Kobayashi, M. Furihata, S. Chung, S. Ashida, T. Miki, T. Fujioka, T. Shuin, Y. Nakamura, H. Nakagawa, Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism, Cancer Res. 69 (2009) 8133-8140.
43. A. Jayakumar, M.H. Tai, W.Y. Huang, W. al-Feel, M. Hsu, L. Abu-Elheiga, S.S. Chirala, S.J. Wakil, Human fatty acid synthase: properties and molecular cloning, Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 8695-8699.
44. G. Medes, A. Thomas, S. Weinhouse, Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro, Cancer Res. 13 (1953) 27-29.
45. F.P. Kuhajda, Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology, Nutrition 16 (2000) 202-208. (Pubitemid 30114274)
46. C.R. Santos, A. Schulze, Lipid metabolism in cancer, FEBS J. 279 (2012) 2610-2623.
47. M.S. Shurbaji, J.H. Kalbfleisch, T.S. Thurmond, Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer, Hum. Pathol. 27 (1996) 917-921. (Pubitemid 26304570)
48. J.L. Little, F.B. Wheeler, D.R. Fels, C. Koumenis, S.J. Kridel, Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells, Cancer Res. 67 (2007) 1262-1269.
49. J.V. Swinnen, M. Esquenet, K. Goossens, W. Heyns, G. Verhoeven, Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP, Cancer Res. 57 (1997) 1086-1090. (Pubitemid 27138606)
50. J.V. Swinnen, H. Heemers, L. Deboel, F. Foufelle, W. Heyns, G. Verhoeven, Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway, Oncogene 19 (2000) 5173-5181.
51. W.C. Huang, X. Li, J. Liu, J. Lin, L.W. Chung, Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells, Mol. Cancer Res. 10 (2012) 133-142.
52. E. De Schrijver, K. Brusselmans, W. Heyns, G. Verhoeven, J.V. Swinnen, RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells, Cancer Res. 63 (2003) 3799-3804. (Pubitemid 36793069)
53. S.J. Kridel, F. Axelrod, N. Rozenkrantz, J.W. Smith, Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity, Cancer Res. 64 (2004) 2070-2075. (Pubitemid 38339455)
54. K. Brusselmans, E. De Schrijver, G. Verhoeven, J.V. Swinnen, RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells, Cancer Res. 65 (2005) 6719-6725. (Pubitemid 41060709)
55. G. Hatzivassiliou, F. Zhao, D.E. Bauer, C. Andreadis, A.N. Shaw, D. Dhanak, S.R. Hingorani, D.A. Tuveson, C.B. Thompson, ATP citrate lyase inhibition can suppress tumor cell growth, Cancer Cell 8 (2005) 311-321. (Pubitemid 41443416)
56. A. Beckers, S. Organe, L. Timmermans, K. Scheys, A. Peeters, K. Brusselmans, G. Verhoeven, J.V. Swinnen, Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells, Cancer Res. 67 (2007) 8180-8187. (Pubitemid 47395154)
57. J.S. Moon, W.J. Jin, J.H. Kwak, H.J. Kim, M.J. Yun, J.W. Kim, S.W. Park, K.S. Kim, Androgen stimulates glycolysis for de novo lipid synthesisbyincreasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6- bisphosphatase 2 in prostate cancer cells, Biochem. J. 433 (2011) 225-233.
58. R.J. DeBerardinis, A. Mancuso, E. Daikhin, I. Nissim, M. Yudkoff, S. Wehrli, C.B. Thompson, Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 19345-19350.
59. X. Liu, Y.M. Fu, G.G. Meadows, Differential effects of specific amino acid restriction on glucose metabolism, reduction/oxidation status and mitochondrial damage in DU145 and PC3 prostate cancer cells, Oncol. Lett. 2 (2011) 349-355.
60. A.R. Mullen, W.W. Wheaton, E.S. Jin, P.H. Chen, L.B. Sullivan, T. Cheng, Y. Yang, W.M. Linehan, N.S. Chandel, R.J. DeBerardinis, Reductive carboxylation supports growth in tumour cells with defective mitochondria, Nature 481 (2012) 385-388.
61. C.M. Metallo, P.A. Gameiro, E.L. Bell, K.R. Mattaini, J. Yang, K. Hiller, C.M. Jewell, Z.R. Johnson, D.J. Irvine, L. Guarente, J.K. Kelleher, M.G. Vander Heiden, O. Iliopoulos, G. Stephanopoulos, Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia, Nature 481 (2012) 380-384.
62. J.V. Swinnen, P.P. Van Veldhoven, L. Timmermans, E. De Schrijver, K. Brusselmans, F. Vanderhoydonc, T. Van de Sande, H. Heemers, W. Heyns, G. Verhoeven, Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains, Biochem. Biophys. Res. Commun. 302 (2003) 898-903. (Pubitemid 36294061)
63. T. Van de Sande, T. Roskams, E. Lerut, S. Joniau, H. Van Poppel, G. Verhoeven, J.V. Swinnen, High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB, J. Pathol. 206 (2005) 214-219. (Pubitemid 40754025)
64. W. Zhou, P.J. Simpson, J.M. McFadden, C.A. Townsend, S.M. Medghalchi, A. Vadlamudi, M.L. Pinn, G.V. Ronnett, F.P. Kuhajda, Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells, Cancer Res. 63 (2003) 7330-7337. (Pubitemid 37413474)
65. S.K. Parks, J. Chiche, J. Pouyssegur, pH control mechanisms of tumor survival and growth, J. Cell. Physiol. 226 (2011) 299-308.
66. P.W. Hochachka, Living Without Oxygen, Harvard University Press, Cambridge, USA, 1980.
67. P.S. Ward, C.B. Thompson, Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate, Cancer Cell 21 (2012) 297-308.
68. E. Rysman, K. Brusselmans, K. Scheys, L. Timmermans, R. Derua, S. Munck, P.P. Van Veldhoven, D. Waltregny, V.W. Daniels, J. Machiels, F. Vanderhoydonc, K. Smans, E. Waelkens, G. Verhoeven, J.V. Swinnen, De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation, Cancer Res. 70 (2010) 8117-8126.
69. S. Staubach, F.G. Hanisch, Lipid rafts: signaling and sorting platforms of cells and their roles in cancer, Expert Rev. Proteomics 8 (2011) 263-277.
70. N. Willemarck, E. Rysman, K. Brusselmans, G. Van Imschoot, F. Vanderhoydonc, K. Moerloose, E. Lerut, G. Verhoeven, F. van Roy, K. Vleminckx, J.V. Swinnen, Aberrant activation of fatty acid synthesis suppresses primary cilium formation and distorts tissue development, Cancer Res. 70 (2010) 9453-9462.
71. E.J. Michaud, B.K. Yoder, The primary cilium in cell signaling and cancer, Cancer Res. 66 (2006) 6463-6467. (Pubitemid 44085596)
72. O.V. Plotnikova, E.A. Golemis, E.N. Pugacheva, Cell cycle-dependent ciliogenesis and cancer, Cancer Res. 68 (2008) 2058-2061. (Pubitemid 351521774)
73. R.A. Igal, Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer, Carcinogenesis 31 (2010) 1509-1515.
74. J.E. Schaffer, Lipotoxicity: when tissues overeat, Curr. Opin. Lipidol. 14 (2003) 281-287. (Pubitemid 36688207)
75. A.E. Leonard, S.L. Pereira, H. Sprecher, Y.S. Huang, Elongation of long-chain fatty acids, Prog. Lipid Res. 43 (2004) 36-54. (Pubitemid 37433866)
76. A. Kihara, Very long-chain fatty acids: elongation, physiology and related disorders, J. Biochem. 152 (2012) 387-395.
77. S.K. Suneja, P. Osei, L. Cook, M.N. Nagi, D.L. Cinti, Enzyme site-specific changes in hepatic microsomal fatty acid chain elongation in streptozotocin-induced diabetic rats, Biochim. Biophys. Acta 1042 (1990) 81-85. (Pubitemid 20021617)
78. R.V. Farese Jr., T.C. Walther, Lipid droplets finally get a little R-E-S-P-E-C-T, Cell 139 (2009) 855-860.
79. D.K. Nomura, J.Z. Long, S. Niessen, H.S. Hoover, S.W. Ng, B.F. Cravatt, Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis, Cell 140 (2010) 49-61.
80. D.T. Price, R.E. Coleman, R.P. Liao, C.N. Robertson, T.J. Polascik, T.R. DeGrado, Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer, J. Urol. 168 (2002) 273-280. (Pubitemid 34640843)
81. P.J. Effert, R. Bares, S. Handt, J.M. Wolff, U. Bull, G. Jakse, Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose, J. Urol. 155 (1996) 994-998.
82. Y. Liu, L.S. Zuckier, N.V. Ghesani, Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic approach, Anticancer. Res. 30 (2010) 369-374.
83. S. Zha, S. Ferdinandusse, J.L. Hicks, S. Denis, T.A. Dunn, R.J. Wanders, J. Luo, A.M. De Marzo, W.B. Isaacs, Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer, Prostate 63 (2005) 316-323. (Pubitemid 40664342)
84. J. Luo, S. Zha, W.R. Gage, T.A. Dunn, J.L. Hicks, C.J. Bennett, C.M. Ewing, E.A. Platz, S. Ferdinandusse, R.J. Wanders, J.M. Trent, W.B. Isaacs, A.M. De Marzo, Alphamethylacyl-CoA racemase: a new molecular marker for prostate cancer, Cancer Res. 62 (2002) 2220-2226. (Pubitemid 34411693)
85. C. Kumar-Sinha, R.B. Shah, B. Laxman, S.A. Tomlins, J. Harwood, W. Schmitz, E. Conzelmann, M.G. Sanda, J.T. Wei, M.A. Rubin, A.M. Chinnaiyan, Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer, Am. J. Pathol. 164 (2004) 787-793. (Pubitemid 38235461)
86. L.C. Costello, Y. Liu, R.B. Franklin, M.C. Kennedy, Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism of prostate epithelial cells, J. Biol. Chem. 272 (1997) 28875-28881. (Pubitemid 27498168)
87. S. Arver, Zinc and zinc ligands in human seminal plasma. III. The principal low molecular weight zinc ligand in prostatic secretion and seminal plasma, Acta Physiol. Scand. 116 (1982) 67-73. (Pubitemid 12005505)
88. W.C. Ford, A. Harrison, The role of citrate in determining the activity of calcium ions in human semen, Int. J. Androl. 7 (1984) 198-202. (Pubitemid 14087010)
89. S. Marengo, Prostate physiology and regulation, in: M.I. Resnick, I.M. Thompson (Eds.), Advanced Therapy of Prostate Disease, Bs Decker Inc., Hamilton, Ontario, Canada, 2000, pp. 92-100.
90. F.C. Delvecchio, R.M. Brizuela, S.R. Khan, K. Byer, Z. Li, P. Zhong, G.M. Preminger, Citrate and vitamin E blunt the shock wave-induced free radical surge in an in vitro cell culture model, Urol. Res. 33 (2005) 448-452. (Pubitemid 41778786)
91. L.C. Costello, R.B. Franklin, The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots, Mol. Cancer 5 (2006) 17.
92. L.C. Costello, R.B. Franklin, The intermediary metabolism of the prostate: a key to understanding the pathogenesis and progression ofprostate malignancy, Oncology 59 (2000) 269-282.
93. R.J. Deberardinis, J.J. Lum, C.B. Thompson, Phosphatidylinositol 3-kinase-dependent modulation of carnitine palmitoyltransferase 1A expression regulates lipid metabolism during hematopoietic cell growth, J. Biol. Chem. 281 (2006) 37372-37380. (Pubitemid 46042041)
94. L.S. Pike, A.L. Smift, N.J. Croteau, D.A. Ferrick, M. Wu, Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells, Biochim. Biophys. Acta 1807 (2011) 726-734.
95. I. Samudio, R. Harmancey, M. Fiegl, H. Kantarjian, M. Konopleva, B. Korchin, K. Kaluarachchi, W. Bornmann, S. Duvvuri, H. Taegtmeyer, M. Andreeff, Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction, J. Clin. Invest. 120 (2010) 142-156.
96. K. Pelton, M.R. Freeman, K.R. Solomon, Cholesterol and prostate cancer, Curr. Opin. Pharmacol. 12 (2012) 751-759.
97. L. Zhuang, J. Kim, R.M. Adam, K.R. Solomon, M.R. Freeman, Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts, J. Clin. Invest. 115 (2005) 959-968. (Pubitemid 40489400)
98. G. Llaverias, C. Danilo, Y. Wang, A.K. Witkiewicz, K. Daumer, M.P. Lisanti, P.G. Frank, A Western-type diet accelerates tumor progression in an autochthonous mouse model of prostate cancer, Am. J. Pathol. 177 (2010) 3180-3191.
99. D.G. Hardie, D. Carling, The AMP-activated protein kinase-fuel gauge of the mammalian cell? Eur. J. Biochem. 246 (1997) 259-273. (Pubitemid 27232500)
100. D. Eberle, B. Hegarty, P. Bossard, P. Ferre, F. Foufelle, SREBP transcription factors: master regulators of lipid homeostasis, Biochimie 86 (2004) 839-848. (Pubitemid 39602764)
101. Y. Chen, M. Hughes-Fulford, Human prostate cancer cells lack feedback regulation of low-density lipoprotein receptor and its regulator, SREBP2, Int. J. Cancer 91 (2001) 41-45.
102. S.L. Ettinger, R. Sobel, T.G. Whitmore, M. Akbari, D.R. Bradley, M.E. Gleave, C.C. Nelson, Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence, Cancer Res. 64 (2004) 2212-2221. (Pubitemid 38339475)
103. M.R. Freeman, W. Yang, D. Di Vizio, Caveolin-1 and prostate cancer progression, Adv. Exp. Med. Biol. 729 (2012) 95-110.
104. T.M. Williams, G.S. Hassan, J. Li, A.W. Cohen, F. Medina, P.G. Frank, R.G. Pestell, D. Di Vizio, M. Loda, M.P. Lisanti, Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice, J. Biol. Chem. 280 (2005) 25134-25145. (Pubitemid 40934606)
105. M.R. Freeman, K.R. Solomon, Cholesterol and prostate cancer, J. Cell. Biochem. 91 (2004) 54-69.
106. M. Roy, H.J. Kung, P.M. Ghosh, Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins, Am. J. Cancer Res. 1 (2011) 542-561.
107. D.J. Mener, Prostate specific antigen reduction following statin therapy: Mechanism of action and review of the literature, IUBMB Life 62 (2010) 584-590.
108. J.W. Clendening, L.Z. Penn, Targeting tumor cell metabolism with statins, Oncogene 31 (2012) 4967-4978.
109. E.A. Mostaghel, S.T. Page, D.W. Lin, L. Fazli, I.M. Coleman, L.D. True, B. Knudsen, D.L. Hess, C.C. Nelson, A.M. Matsumoto, W.J. Bremner, M.E. Gleave, P.S. Nelson, Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer, Cancer Res. 67 (2007) 5033-5041. (Pubitemid 46910214)
110. J.A. Locke, E.S. Guns, A.A. Lubik, H.H. Adomat, S.C. Hendy, C.A. Wood, S.L. Ettinger, M.E. Gleave, C.C. Nelson, Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer, Cancer Res. 68 (2008) 6407-6415.
111. P.R. Dillard, M.F. Lin, S.A. Khan, Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol, Mol. Cell. Endocrinol. 295 (2008) 115-120.
112. R.B. Montgomery, E.A. Mostaghel, R. Vessella, D.L. Hess, T.F. Kalhorn, C.S. Higano, L.D. True, P.S. Nelson, Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth, Cancer Res. 68 (2008) 4447-4454.
113. E.A. Mostaghel, K.R. Solomon, K. Pelton, M.R. Freeman, R.B. Montgomery, Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors, PLoS One 7 (2012) e30062.
114. J.R. Cantor, D.M. Sabatini, Cancer cell metabolism: one hallmark, many faces, Cancer Discov. 2 (2012) 881-898.
115. Y.A. Yang, W.F. Han, P.J. Morin, F.J. Chrest, E.S. Pizer, Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase, Exp. Cell Res. 279 (2002) 80-90.
116. T. Mashima, H. Seimiya, T. Tsuruo, De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy, Br. J. Cancer 100 (2009) 1369-1372.
117. B.S. Taylor, N. Schultz, H. Hieronymus, A. Gopalan, Y. Xiao, B.S. Carver, V.K. Arora, P. Kaushik, E. Cerami, B. Reva, Y. Antipin, N. Mitsiades, T. Landers, I. Dolgalev, J.E. Major, M. Wilson, N.D. Socci, A.E. Lash, A. Heguy, J.A. Eastham, H.I. Scher, V.E. Reuter, P.T. Scardino, C. Sander, C.L. Sawyers, W.L. Gerald, Integrative genomic profiling of human prostate cancer, Cancer Cell 18 (2010) 11-22.
118. S. Wang, J. Gao, Q. Lei, N. Rozengurt, C. Pritchard, J. Jiao, G.V. Thomas, G. Li, P. Roy-Burman, P.S. Nelson, X. Liu, H. Wu, Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer, Cancer Cell 4 (2003) 209-221. (Pubitemid 37163835)
119. T. Van de Sande, E. De Schrijver, W. Heyns, G. Verhoeven, J.V. Swinnen, Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells, Cancer Res. 62 (2002) 642-646. (Pubitemid 34126933)
120. H.Q. Wang, D.A. Altomare, K.L. Skele, P.I. Poulikakos, F.P. Kuhajda, A. Di Cristofano, J.R. Testa, Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells, Oncogene 24 (2005) 3574-3582. (Pubitemid 40756227)
121. K. Tomek, R. Wagner, F. Varga, C.F. Singer, H. Karlic, T.W. Grunt, Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer, Mol. Cancer Res. 9 (2011) 1767-1779.
122. J.D. Horton, J.L. Goldstein, M.S. Brown, SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver, J. Clin. Invest. 109 (2002) 1125-1131. (Pubitemid 34496588)
123. T. Porstmann, C.R. Santos, B. Griffiths, M. Cully, M. Wu, S. Leevers, J.R. Griffiths, Y.L. Chung, A. Schulze, SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth, Cell Metab. 8 (2008) 224-236.
124. K. Duvel, J.L. Yecies, S. Menon, P. Raman, A.I. Lipovsky, A.L. Souza, E. Triantafellow, Q. Ma, R. Gorski, S. Cleaver, M.G. Vander Heiden, J.P. MacKeigan, P.M. Finan, C.B. Clish, L.O. Murphy, B.D. Manning, Activation of a metabolic gene regulatory network downstream of mTOR complex 1, Mol. Cell 39 (2010) 171-183.
125. S. Li, M.S. Brown, J.L. Goldstein, Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis, Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 3441-3446.
126. D.C. Berwick, I. Hers, K.J. Heesom, S.K. Moule, J.M. Tavare, The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes, J. Biol. Chem. 277 (2002) 33895-33900.
127. T. Porstmann, B. Griffiths, Y.L. Chung, O. Delpuech, J.R. Griffiths, J. Downward, A. Schulze, PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP, Oncogene 24 (2005) 6465-6481. (Pubitemid 41486630)
128. S. Signoretti, R. Montironi, J. Manola, A. Altimari, C. Tam, G. Bubley, S. Balk, G. Thomas, I. Kaplan, L. Hlatky, P. Hahnfeldt, P. Kantoff, M. Loda, Her-2-neu expression and progression toward androgen independence in human prostate cancer, J. Natl. Cancer Inst. 92 (2000) 1918-1925. (Pubitemid 32036922)
129. C. Kumar-Sinha, K.W. Ignatoski, M.E. Lippman, S.P. Ethier, A.M. Chinnaiyan, Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis, Cancer Res. 63 (2003) 132-139. (Pubitemid 36070431)
130. S. Yoon, M.Y. Lee, S.W. Park, J.S. Moon, Y.K. Koh, Y.H. Ahn, B.W. Park, K.S. Kim, Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells, J. Biol. Chem. 282 (2007) 26122-26131. (Pubitemid 47443806)
131. P.M. Alli, M.L. Pinn, E.M. Jaffee, J.M. McFadden, F.P. Kuhajda, Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice, Oncogene 24 (2005) 39-46. (Pubitemid 40143863)
132. C.M. Koh, C.J. Bieberich, C.V. Dang, W.G. Nelson, S. Yegnasubramanian, A.M. De Marzo, MYC and prostate cancer, Genes Cancer 1 (2010) 617-628.
133. F. Morrish, J. Noonan, C. Perez-Olsen, P.R. Gafken, M. Fitzgibbon, J. Kelleher, M. VanGilst, D. Hockenbery, Myc-dependent mitochondrial generation of acetyl-CoA contributes to fatty acid biosynthesis and histone acetylation during cell cycle entry, J. Biol. Chem. 285 (2010) 36267-36274.
134. F. Morrish, N. Neretti, J.M. Sedivy, D.M. Hockenbery, The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry, Cell Cycle 7 (2008) 1054-1066.
135. R.J. Shaw, LKB1 and AMP-activated protein kinase control of mTOR signalling and growth, Acta Physiol. (Oxf.) 196 (2009) 65-80.
136. S. Fogarty, D.G. Hardie, Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer, Biochim. Biophys. Acta 1804 (2010) 581-591.
137. G. Zhou, R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, N. Musi, M.F. Hirshman, L.J. Goodyear, D.E. Moller, Role of AMP-activated protein kinase in mechanism of metformin action, J. Clin. Invest. 108 (2001) 1167-1174. (Pubitemid 32995375)
138. Y. Li, S. Xu, M.M. Mihaylova, B. Zheng, X. Hou, B. Jiang, O. Park, Z. Luo, E. Lefai, J.Y. Shyy, B. Gao, M. Wierzbicki, T.J. Verbeuren, R.J. Shaw, R.A. Cohen, M. Zang, AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice, Cell Metab. 13 (2011) 376-388.
139. B. Grundmark, H. Garmo, M. Loda, C. Busch, L. Holmberg, B. Zethelius, The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes, Cancer Epidemiol. Biomarkers Prev. 19 (2010) 2088-2096.
140. R. Morales, C. Suarez, J. Ropero, I. Nunez, J. Planas, J. Placer, C. María Valverde, X. Maldonado, J. Morote, J. Carles, The influence of metabolic syndrome on prostate cancer risk detection and its aggressiveness, J. Clin. Oncol. 30 (Suppl. 5) (2012), (abstr 226).
141. Z. Luo, A.K. Saha, X. Xiang, N.B. Ruderman, AMPK, the metabolic syndrome and cancer, Trends Pharmacol. Sci. 26 (2005) 69-76. (Pubitemid 40170168)
142. A. Shamma, Y. Takegami, T. Miki, S. Kitajima, M. Noda, T. Obara, T. Okamoto, C. Takahashi, Rb Regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation, Cancer Cell 15 (2009) 255-269.
143. W.A. Freed-Pastor, H. Mizuno, X. Zhao, A. Langerod, S.H. Moon, R. Rodriguez-Barrueco, A. Barsotti, A. Chicas, W. Li, A. Polotskaia, M.J. Bissell, T.F. Osborne, B. Tian, S.W. Lowe, J.M. Silva, A.L. Borresen-Dale, A.J. Levine, J. Bargonetti, C. Prives, Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway, Cell 148 (2012) 244-258.
144. C.W.t. Pemble, L.C. Johnson, S.J. Kridel, W.T. Lowther, Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat, Nat. Struct. Mol. Biol. 14 (2007) 704-709. (Pubitemid 47220052)
145. R. Flavin, S. Peluso, P.L. Nguyen, M. Loda, Fatty acid synthase as a potential therapeutic target in cancer, Future Oncol. 6 (2010) 551-562.
146. R. Flavin, G. Zadra, M. Loda, Metabolic alterations and targeted therapies in prostate cancer, J. Pathol. 223 (2011) 283-294.
147. T. Migita, T. Narita, K. Nomura, E. Miyagi, F. Inazuka, M. Matsuura, M. Ushijima, T. Mashima, H. Seimiya, Y. Satoh, S. Okumura, K. Nakagawa, Y. Ishikawa, ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer, Cancer Res. 68 (2008) 8547-8554.
148. N. Zaidi, I. Royaux, J.V. Swinnen, K. Smans, ATP citrate lyase knockdown induces growth arrest and apoptosis through different cell- and environment-dependent mechanisms, Mol. Cancer Ther. 11 (2012) 1925-1935.
149. G. Liu, J.K. Lynch, J. Freeman, B. Liu, Z. Xin, H. Zhao, M.D. Serby, P.R. Kym, T.S. Suhar, H.T. Smith, N. Cao, R. Yang, R.S. Janis, J.A. Krauser, S.P. Cepa, D.W. Beno, H.L. Sham, C.A. Collins, T.K. Surowy, H.S. Camp, Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors, J. Med. Chem. 50 (2007) 3086-3100. (Pubitemid 47001252)
150. D.O. Koltun, T.M. Zilbershtein, V.A. Migulin, N.I. Vasilevich, E.Q. Parkhill, A.I. Glushkov, M.J. McGregor, S.A. Brunn, N. Chu, J. Hao, N. Mollova, K. Leung, J.W. Chisholm, J. Zablocki, Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors, Bioorg. Med. Chem. Lett. 19 (2009) 4070-4074.
151. S.T. Kochuparambil, B. Al-Husein, A. Goc, S. Soliman, P.R. Somanath, Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression, J. Pharmacol. Exp. Ther. 336 (2011) 496-505.
152. J.M. Evans, L.A. Donnelly, A.M. Emslie-Smith, D.R. Alessi, A.D. Morris, Metformin and reduced risk of cancer in diabetic patients, BMJ 330 (2005) 1304-1305. (Pubitemid 40813563)
153. S.L. Bowker, S.R. Majumdar, P. Veugelers, J.A. Johnson, Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider, Diabetes Care 29 (2006) 1990-1991. (Pubitemid 44156679)
154. J.L. Wright, J.L. Stanford, Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study, Cancer Causes Control 20 (2009) 1617-1622.
155. S. Jiralerspong, S.L. Palla, S.H. Giordano, F. Meric-Bernstam, C. Liedtke, C.M. Barnett, L. Hsu, M.C. Hung, G.N. Hortobagyi, A.M. Gonzalez-Angulo, Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer, J. Clin. Oncol. 27 (2009) 3297-3302.
156. M. Zakikhani, R.J. Dowling, N. Sonenberg, M.N. Pollak, The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase, Cancer Prev. Res. (Phila.) 1 (2008) 369-375.
157. I. Ben Sahra, K. Laurent, A. Loubat, S. Giorgetti-Peraldi, P. Colosetti, P. Auberger, J.F. Tanti, Y. Le Marchand-Brustel, F. Bost, The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level, Oncogene 27 (2008) 3576-3586. (Pubitemid 351793803)
158. I. Ben Sahra, C. Regazzetti, G. Robert, K. Laurent, Y. Le Marchand-Brustel, P. Auberger, J.F. Tanti, S. Giorgetti-Peraldi, F. Bost, Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1, Cancer Res. 71 (2011) 4366-4372.
159. D.G. Hardie, Neither LKB1 nor AMPK are the direct targets of metformin, Gastroenterology 131 (2006) 973, (author reply 974-975). (Pubitemid 44307086)
160. D.G. Hardie, AMP-activated protein kinase as a drug target, Annu. Rev. Pharmacol. Toxicol. 47 (2007) 185-210.
161. R.M. Moretti, M. Montagnani Marelli, M. Motta, P. Limonta, Oncostatic activity of a thiazolidinedione derivative on human androgen-dependent prostate cancer cells, Int. J. Cancer 92 (2001) 733-737. (Pubitemid 32385718)
162. X. Xiang, A.K. Saha, R. Wen, N.B. Ruderman, Z. Luo, AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms, Biochem. Biophys. Res. Commun. 321 (2004) 161-167. (Pubitemid 39055618)
163. B. Guigas, K. Sakamoto, N. Taleux, S.M. Reyna, N. Musi, B. Viollet, L. Hue, Beyond AICA riboside: in search of new specific AMP-activated protein kinase activators, IUBMB Life 61 (2009) 18-26.
164. B. Xiao, R. Heath, P. Saiu, F.C. Leiper, P. Leone, C. Jing, P.A. Walker, L. Haire, J.F. Eccleston, C.T. Davis, S.R. Martin, D. Carling, S.J. Gamblin, Structural basis for AMP binding to mammalian AMP-activated protein kinase, Nature 449 (2007) 496-500. (Pubitemid 47509548)
165. B. Cool, B. Zinker, W. Chiou, L. Kifle, N. Cao, M. Perham, R. Dickinson, A. Adler, G. Gagne, R. Iyengar, G. Zhao, K. Marsh, P. Kym, P. Jung, H.S. Camp, E. Frevert, Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome, Cell Metab. 3 (2006) 403-416. (Pubitemid 43811782)
166. O. Goransson, A. McBride, S.A. Hawley, F.A. Ross, N. Shpiro, M. Foretz, B. Viollet, D.G. Hardie, K. Sakamoto, Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase, J. Biol. Chem. 282 (2007) 32549-32560. (Pubitemid 350159310)
167. M.J. Sanders, Z.S. Ali, B.D. Hegarty, R. Heath, M.A. Snowden, D. Carling, Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family, J. Biol. Chem. 282 (2007) 32539-32548. (Pubitemid 350159309)
168. G.R. Steinberg, B.E. Kemp, AMPK in health and disease, Physiol. Rev. 89 (2009) 1025-1078.
169. X. Huang, S. Wullschleger, N. Shpiro, V.A. McGuire, K. Sakamoto, Y.L. Woods, W. McBurnie, S. Fleming, D.R. Alessi, Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice, Biochem. J. 412 (2008) 211-221. (Pubitemid 351758227)
170. D. Moreno, E. Knecht, B. Viollet, P. Sanz, A769662, a novel activator of AMP-activated protein kinase, inhibits non-proteolytic components of the 26S proteasome by an AMPK-independent mechanism, FEBS Lett. 582 (2008) 2650-2654.
171. C. Garcia-Garcia, C. Fumarola, N. Navaratnam, D. Carling, A. Lopez-Rivas, AMPK-independent down-regulation of cFLIP and sensitization to TRAIL-induced apoptosis by AMPK activators, Biochem. Pharmacol. 79 (2010) 853-863.
172. T. Pang, Z.S. Zhang, M. Gu, B.Y. Qiu, L.F. Yu, P.R. Cao, W. Shao, M.B. Su, J.Y. Li, F.J. Nan, J. Li, Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells, J. Biol. Chem. 283 (2008) 16051-16060.
173. K.H. Lee, E.C. Hsu, J.H. Guh, H.C. Yang, D. Wang, S.K. Kulp, C.L. Shapiro, C.S. Chen, Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator, J. Biol. Chem. 286 (2011) 39247-39258.
174. T. Bui, C.B. Thompson, Cancer's sweet tooth, Cancer Cell 9 (2006) 419-420. (Pubitemid 43832194)
175. R.A. Gatenby, R.J. Gillies, A microenvironmental model of carcinogenesis, Nat. Rev. Cancer 8 (2008) 56-61.
176. C. Plathow, W.A. Weber, Tumor cell metabolism imaging, J. Nucl. Med. 49 (Suppl. 2) (2008) 43S-63S. (Pubitemid 351948036)
177. G.J. Kelloff, J.M. Hoffman, B. Johnson, H.I. Scher, B.A. Siegel, E.Y. Cheng, B.D. Cheson, J. O'Shaughnessy, K.Z. Guyton, D.A. Mankoff, L. Shankar, S.M. Larson, C.C. Sigman, R.L. Schilsky, D.C. Sullivan, Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development, Clin. Cancer Res. 11 (2005) 2785-2808. (Pubitemid 40525178)
178. J. Czernin, M.R. Benz, M.S. Allen-Auerbach, PET imaging of prostate cancer using C-acetate, PET Clin. 4 (2009) 163-172.
179. K.M. Emonds, J.V. Swinnen, W.M. van Weerden, F. Vanderhoydonc, J. Nuyts, L. Mortelmans, F.M. Mottaghy, Do androgens control the uptake of 18F-FDG, 11C-choline and 11C-acetate in human prostate cancer cell lines? Eur. J. Nucl. Med. Mol. Imaging 38 (2011) 1842-1853.
180. J.J. Fox, H. Schoder, S.M. Larson, Molecular imaging of prostate cancer, Curr. Opin. Urol. 22 (2012) 320-327.
181. A.L. Vavere, S.J. Kridel, F.B. Wheeler, J.S. Lewis, 1-11C-acetate as a PET radiophar-maceutical for imaging fatty acid synthase expression in prostate cancer, J. Nucl. Med. 49 (2008) 327-334. (Pubitemid 351225673)
182. J.P. Nobes, S.E. Langley, R.W. Laing, Metabolic syndrome and prostate cancer: a review, Clin. Oncol. (R. Coll. Radiol.) 21 (2009) 183-191.
183. M.J. Khandekar, P. Cohen, B.M. Spiegelman, Molecular mechanisms of cancer development in obesity, Nat. Rev. Cancer 11 (2011) 886-895.
184. S.J. Freedland, Obesity and prostate cancer: a growing problem, Clin. Cancer Res. 11 (2005) 6763-6766. (Pubitemid 41428728)
185. K. Rabe, M. Lehrke, K.G. Parhofer, U.C. Broedl, Adipokines and insulin resistance, Mol. Med. 14 (2008) 741-751.
186. M.E. Grossmann, N.K. Mizuno, M.J. Bonorden, A. Ray, I. Sokolchik, M.L. Narasimhan, M.P. Cleary, Role of the adiponectin leptin ratio in prostate cancer, Oncol. Res. 18 (2009) 269-277.
187. K. Michalakis, C.J. Williams, N. Mitsiades, J. Blakeman, S. Balafouta-Tselenis, A. Giannopoulos, C.S. Mantzoros, Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study, Cancer Epidemiol. Biomarkers Prev. 16 (2007) 308-313. (Pubitemid 46383351)
188. H. Li, M.J. Stampfer, L. Mucci, N. Rifai, W. Qiu, T. Kurth, J. Ma, A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival, Clin. Chem. 56 (2010) 34-43.
189. J.D. Bub, T. Miyazaki, Y. Iwamoto, Adiponectin as a growth inhibitor in prostate cancer cells, Biochem. Biophys. Res. Commun. 340 (2006) 1158-1166. (Pubitemid 43083400)
190. G. Zadra, C. Priolo, A. Patnaik, M. Loda, New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK, Clin. Cancer Res. 16 (2010) 3322-3328.
191. J. Ropero Morote, J. Planas, J.M. Bastaros, G. Delgado, J. Placer, A. Celma, I.M. de Torres, J. Carles, J. Reventos, A. Doll, Metabolic syndrome increases the risk of aggressive prostate cancer detection, BJU Int. (2012).
192. M. Horikoshi, K. Hara, J. Ohashi, K. Miyake, K. Tokunaga, C. Ito, M. Kasuga, R. Nagai, T. Kadowaki, A polymorphism in the AMPKalpha2 subunit gene is associated with insulin resistance and type 2 diabetes in the Japanese population, Diabetes 55 (2006) 919-923. (Pubitemid 44100164)
193. H. Matsui, K. Suzuki, N. Ohtake, S. Nakata, T. Takeuchi, H. Yamanaka, I. Inoue, Genomewide linkage analysis of familial prostate cancer in the Japanese population, J. Hum. Genet. 49 (2004) 9-15. (Pubitemid 38186119)
194. P.L. Nguyen, J. Ma, J.E. Chavarro, M.L. Freedman, R. Lis, G. Fedele, C. Fiore, W. Qiu, M. Fiorentino, S. Finn, K.L. Penney, A. Eisenstein, F.R. Schumacher, L.A. Mucci, M.J. Stampfer, E. Giovannucci, M. Loda, Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival, J. Clin. Oncol. 28 (2010) 3958-3964.
195. M.M. Center, A. Jemal, J. Lortet-Tieulent, E. Ward, J. Ferlay, O. Brawley, F. Bray, International variation in prostate cancer incidence and mortality rates, Eur. Urol. 61 (2012) 1079-1092.
196. L.K. Dennis, L.G. Snetselaar, B.J. Smith, R.E. Stewart, M.E. Robbins, Problems with the assessment of dietary fat in prostate cancer studies, Am. J. Epidemiol. 160 (2004) 436-444. (Pubitemid 39166976)
197. A.S. Whittemore, L.N. Kolonel, A.H. Wu, E.M. John, R.P. Gallagher, G.R. Howe, J.D. Burch, J. Hankin, D.M. Dreon, D.W. West, et al., Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada, J. Natl. Cancer Inst. 87 (1995) 652-661.
198. S.S. Strom, Y. Yamamura, M.R. Forman, C.A. Pettaway, S.L. Barrera, J. DiGiovanni, Saturated fat intake predicts biochemical failure after prostatectomy, Int. J. Cancer 122 (2008) 2581-2585. (Pubitemid 351590493)
199. S.Y. Park, L.R. Wilkens, S.M. Henning, L. Le Marchand, K. Gao, M.T. Goodman, S.P. Murphy, B.E. Henderson, L.N. Kolonel, Circulating fatty acids and prostate cancer risk in a nested case-control study: the Multiethnic Cohort, Cancer Causes Control 20 (2009) 211-223.
200. F.L. Crowe, N.E. Allen, P.N. Appleby, K. Overvad, I.V. Aardestrup, N.F. Johnsen, A. Tjonneland, J. Linseisen, R. Kaaks, H. Boeing, J. Kroger, A. Trichopoulou, A. Zavitsanou, D. Trichopoulos, C. Sacerdote, D. Palli, R. Tumino, C. Agnoli, L.A. Kiemeney, H.B. Bueno-de-Mesquita, M.D. Chirlaque, E. Ardanaz, N. Larranaga, J.R. Quiros, M.J. Sanchez, C.A. Gonzalez, P. Stattin, G. Hallmans, S. Bingham, K.T. Khaw, S. Rinaldi, N. Slimani, M. Jenab, E. Riboli, T.J. Key, Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition, Am. J. Clin. Nutr. 88 (2008) 1353-1363.
201. M.D. Jackson, S.P. Walker, C.M. Simpson-Smith, C.M. Lindsay, G. Smith, N. McFarlane-Anderson, F.I. Bennett, K.C. Coard, W.D. Aiken, T. Tulloch, T.J. Paul, R.L. Wan, Associations of whole-blood fatty acids and dietary intakes with prostate cancer in Jamaica, Cancer Causes Control 23 (2012) 23-33.
202. J.C. Lloyd, J.A. Antonelli, T.E. Phillips, E.M. Masko, J.A. Thomas, S.H. Poulton, M. Pollak, S.J. Freedland, Effect of isocaloric low fat diet on prostate cancer xenograft progression in a hormone deprivation model, J. Urol. 183 (2010) 1619-1624.
203. E.L. Escobar, M.C. Gomes-Marcondes, H.F. Carvalho, Dietary fatty acid quality affects AR and PPARgamma levels and prostate growth, Prostate 69 (2009) 548-558.
204. A. Trichopoulou, P. Lagiou, H. Kuper, D. Trichopoulos, Cancer and Mediterranean dietary traditions, Cancer Epidemiol. Biomarkers Prev. 9 (2000) 869-873.
205. I.M. Berquin, I.J. Edwards, S.J. Kridel, Y.Q. Chen, Polyunsaturated fatty acid metabolism in prostate cancer, Cancer Metastasis Rev. 30 (2011) 295-309.
206. J.L. Beare-Rogers, L. Gray, E.A. Nera, O.L. Levin, Nutritional properties of poppyseed oil relative to some other oils, Nutr. Metab. 23 (1979) 335-346. (Pubitemid 9158401)
207. G.C. Burdge, P.C. Calder, Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults, Reprod. Nutr. Dev. 45 (2005) 581-597. (Pubitemid 41511883)
208. J.E. Chavarro, M.J. Stampfer, H. Li, H. Campos, T. Kurth, J. Ma, A prospective study of polyunsaturated fatty acid levels in blood and prostate cancer risk, Cancer Epidemiol. Biomarkers Prev. 16 (2007) 1364-1370. (Pubitemid 47076865)
209. S. Wang, J. Wu, J. Suburu, Z. Gu, J. Cai, L.S. Axanova, S.D. Cramer, M.J. Thomas, D.L. Perry, I.J. Edwards, L.A. Mucci, J.A. Sinnott, M.F. Loda, G. Sui, I.M. Berquin, Y.Q. Chen, Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer, Carcinogenesis 33 (2012) 404-412.
210. I.M. Berquin, Y. Min, R. Wu, J. Wu, D. Perry, J.M. Cline, M.J. Thomas, T. Thornburg, G. Kulik, A. Smith, I.J. Edwards, R. D'Agostino, H. Zhang, H. Wu, J.X. Kang, Y.Q. Chen, Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids, J. Clin. Invest. 117 (2007) 1866-1875. (Pubitemid 47036320)
211. J.A. Akinsete, G. Ion, T.R. Witte, W.E. Hardman, Consumption of high omega-3 fatty acid diet suppressed prostate tumorigenesis in C3(1) Tag mice, Carcinogenesis 33 (2012) 140-148.